Wedbush Maintains a “Buy” Rating on Kala Pharmaceuticals (KALA) and $46.0 Target; Altalis Capital Management Has Trimmed Calpine (CPN) Stake

Altalis Capital Management Llc decreased Calpine Corp (CPN) stake by 61.11% reported in 2017Q3 SEC filing. Altalis Capital Management Llc sold 337,053 shares as Calpine Corp (CPN)’s stock rose 19.88%. The Altalis Capital Management Llc holds 214,526 shares with $3.17M value, down from 551,579 last quarter. Calpine Corp now has $5.45 billion valuation. It closed at $15.1 lastly. It is down 5.37% since December 26, 2016 and is downtrending. It has underperformed by 22.07% the S&P500.

Among 5 analysts covering Kala Pharmaceuticals (KALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kala Pharmaceuticals has $46 highest and $2400 lowest target. $34.60’s average target is 90.84% above currents $18.13 stock price. Kala Pharmaceuticals had 7 analyst reports since August 14, 2017 according to SRatingsIntel. The company was initiated on Monday, August 14 by Bank of America. Wedbush maintained the shares of KALA in report on Wednesday, October 25 with “Buy” rating. The stock of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has “Buy” rating given on Monday, August 14 by J.P. Morgan. Wedbush maintained the stock with “Buy” rating in Thursday, November 30 report. Wells Fargo initiated it with “Buy” rating and $2400 target in Monday, August 14 report.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle Mucus Penetrating Particles technology. The company has market cap of $444.57 million. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It currently has negative earnings. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases.

The stock increased 4.98% or $0.86 during the last trading session, reaching $18.13. About 126,834 shares traded. Kala Pharmaceuticals, Inc. (KALA) has 0.00% since December 26, 2016 and is . It has underperformed by 16.70% the S&P500.

Analysts await Kala Pharmaceuticals, Inc. (NASDAQ:KALA) to report earnings on February, 6. After $-0.56 actual EPS reported by Kala Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -33.93% EPS growth.

Among 15 analysts covering Calpine Corporation (NYSE:CPN), 5 have Buy rating, 0 Sell and 10 Hold. Therefore 33% are positive. Calpine Corporation had 42 analyst reports since July 31, 2015 according to SRatingsIntel. Deutsche Bank upgraded the stock to “Buy” rating in Tuesday, July 26 report. The stock of Calpine Corporation (NYSE:CPN) has “Buy” rating given on Tuesday, March 29 by Citigroup. As per Tuesday, November 22, the company rating was downgraded by Bank of America. The company was downgraded on Monday, November 2 by Deutsche Bank. The stock has “Neutral” rating by Guggenheim on Monday, August 21. The stock has “Outperform” rating by RBC Capital Markets on Monday, August 3. On Friday, September 18 the stock rating was initiated by Citigroup with “Buy”. The firm has “Buy” rating by Evercore given on Friday, July 31. SunTrust maintained Calpine Corporation (NYSE:CPN) rating on Wednesday, August 24. SunTrust has “Neutral” rating and $13 target. Morgan Stanley downgraded Calpine Corporation (NYSE:CPN) on Monday, February 6 to “Equal-Weight” rating.

Since August 23, 2017, it had 0 insider purchases, and 3 selling transactions for $17.24 million activity. Hill Thad sold $577,624 worth of stock. MILLER W. THADDEUS had sold 177,627 shares worth $2.69M on Wednesday, December 13. $13.98 million worth of Calpine Corporation (NYSE:CPN) was sold by Fusco Jack A on Wednesday, August 23.